Noriyoshi Iriyama

Noriyoshi Iriyama

Auto-generated profile, based on publicly available information

Noriyoshi Iriyama

Department of Hematology and Rheumatology, National Hospital Organization Saitama Hospital, Wako City, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
YIYuichi Ishikawa
Yuichi Ishikawa
NKNaomi Kawashima
Naomi Kawashima
YAYoshiko Atsuta
Yoshiko Atsuta
ISIsamu Sugiura
Isamu Sugiura
MSMasashi Sawa
Masashi Sawa
HKHitoshi Kiyoi
Hitoshi Kiyoi
Key Points: KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not in those with CBFB-MYH11. NRAS mutation is a poor prognostic factor in AML patients with CBFB-MYH11.

24 January 2012 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
NINoriyoshi Iriyama
Noriyoshi Iriyama
YYYuta Yoshino
Yuta Yoshino
BYBo Yuan
Bo Yuan
AHAkira Horikoshi
Akira Horikoshi
YHYukio Hirabayashi
Yukio Hirabayashi
JTJin Takeuchi
Jin Takeuchi
Background: Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone marrow (BM) has not yet been performed. Profiles of arsenic speciation in plasma of BM were thus investigated and compared with those of PB plasma from a relapsed APL patient. The total arsenic concentrations in high molecular weight fraction (HMW-F) of BM and PB plasma were also determined. Methods: Response assessment was evaluated by BM aspirate examination and fluorescence in situ hybridization analysis. The analyses of total arsenic concentrations and speciation were preformed by inductively coupled plasma mass spectrometry (ICP-MS), and high-performance liquid chromatography (HPLC)/ICP-MS, respectively. Results: Response assessment showed that the patient achieved complete remission. The total arsenic concentrations in BM plasma increased with time during the consecutive administration. The PB plasma concentrations of methylated arsenic metabolites substantially increased after the start of administration, while those of inorganic arsenic were still kept at a low level, followed by substantially increase from day-14 after administration. The arsenic speciation profiles of PB plasma were very similar to those of BM plasma. Furthermore, the total arsenic concentrations of HMW-F in BM plasma were much higher than those in PB plasma. Conclusions: The behaviors of arsenic speciation suggested for the first time that arsenic speciation analysis of PB plasma could be predicative for BM speciation, and showed relatively higher efficiency of drug metabolism in the patient. These results may further provide not only significance of clinical application of ATO, but also a new insight into host defense mechanisms in APL patients undergoing ATO treatment, since HMW proteins-bound arsenic complex could be thought to protect BM from the attack of free arsenic species.

18 September 2017 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
NINoriyoshi Iriyama
Noriyoshi Iriyama
HHHirotsugu Hino
Hirotsugu Hino
SMShota Moriya
Shota Moriya
MHMasaki Hiramoto
Masaki Hiramoto
YHYoshihiro Hatta
Yoshihiro Hatta
KMKeisuke Miyazawa
Keisuke Miyazawa
The D-type cyclin (CCND)-cyclin-dependent kinase 4/6 (CDK4/6) complex has been implicated in multiple myeloma development. We investigated the biological activity of CDK4/6 inhibitor abemaciclib on cell growth and survival in three myeloma cell lines, KMS-12-PE, RPMI 8226, and IM-9. Abemaciclib inhibited myeloma cell growth in a dose-dependent manner in all cell lines, with significant differences seen at a concentration of 320 nM. Treatment with 1 μM abemaciclib increased the fraction of cells in the G0/G1 phase and decreased the fraction in the S-G2/M phases. Further, treatment with abemaciclib at a concentration of 3.2 μM or more showed apparent cytocidal activity accompanied with cytoplasmic vacuolization against myeloma cells. Importantly, abemaciclib induced autophagy in a dose-dependent manner in all three cell lines. These results indicate that the CCND-CDK4/6 complex is closely tied to myeloma cell growth and survival.

22 December 2014 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
NINoriyoshi Iriyama
Noriyoshi Iriyama
SFShin Fujisawa
Shin Fujisawa
CYChikashi Yoshida
Chikashi Yoshida
HWHisashi Wakita
Hisashi Wakita
SCShigeru Chiba
Shigeru Chiba
HSHisashi Sakamaki
Hisashi Sakamaki
To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic‐phase chronic myeloid leukemia (CML‐CP), we performed a clinical trial named the “D‐First study.” Fifty‐two patients with newly diagnosed CML‐CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as <50 copies/μg RNA of BCR‐ABL1 transcript value corrected by GAPDH, which ensures <0.01% of BCR‐ABL1 transcript value according to International Scale (BCR‐ABL1IS). The halving time for BCR‐ABL1 transcripts was calculated using transcript levels before dasatinib treatment, transcript levels after 3 months of treatment, and the treatment time between these two points. In terms of molecular response, 38 of 51 (75%) patients reached major molecular response (MMR) by 12 months, and the rate of DMR by 18 months was 59% (30/51). While both BCR‐ABL1 transcript levels before treatment and a shorter halving time of BCR‐ABL1 transcripts (≤14 days) were significant factors affecting achievement of MMR by 12 months, the Sokal score at diagnosis was not associated with MMR. Importantly, the halving time was the only factor that predicted achievement of DMR by 18 months. We showed that patients with CML‐CP treated with dasatinib can be stratified according to the early treatment response as determined by the halving time of BCR‐ABL1 transcripts. These data emphasize the significance of the early response from dasatinib treatment in achieving a DMR. (ClinicalTrials.gov; NCT01464411) Am. J. Hematol. 90:282–287, 2015.

1 September 2013 in Leukemia Research
Verified
Journal Article
Closed access
NINoriyoshi Iriyama
Noriyoshi Iriyama
YHYoshihiro Hatta
Yoshihiro Hatta
JTJin Takeuchi
Jin Takeuchi
YOYoshiaki Ogawa
Yoshiaki Ogawa
SOShigeki Ohtake
Shigeki Ohtake
TNTomoki Naoe
Tomoki Naoe

1 March 2018 in Leukemia Research
Verified
Journal Article
Closed access
YNYuho Najima
Yuho Najima
CYChikashi Yoshida
Chikashi Yoshida
NINoriyoshi Iriyama
Noriyoshi Iriyama
SFShin Fujisawa
Shin Fujisawa
HWHisashi Wakita
Hisashi Wakita
KIKoiti Inokuchi
Koiti Inokuchi